Circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) for monitoring and predicting response to neoadjuvant therapy (NAT) in high risk early breast cancer patients … Mark Jesus M Magbanua , Laura H Hendrix , Terry Hyslop , William T Barry , Eric P Winer , Clifford Hudis , Deborah Toppmeyer , Lisa Anne Carey , Ann H Partridge , Jean-Yves Pierga , Tanja Fehm , Jose Vidal-Martinez , Dimitrios Mavroudis , Jose A Garcia-Saenz , Justin Stebbing , Paola Gazzaniga , Luis Manso , Rita Zamarchi , Maria Luisa Antelo , Leticia De Mattos-Arruda , Daniele Generali , Carlos Caldas , Elisabetta Munzone , Luc Dirix , Amy L Delson , Harold Burstein , Misbah Qadir , Cynthia Ma , Janet H Scott , Francois-Clement Bidard , John W Park , Hope S Rugo CLINICAL CANCER RESEARCH（2020）
AI 理解论文
溯源树
样例
